African healthcare company EVA Pharma has teamed up with DNA Script and Quantoom Biosciences to bring mRNA and saRNA vaccine manufacturing capabilities to Egypt.
The memorandum of understanding was organised by Africa CDC at the 2nd Vaccine and Other Health Products Manufacturing Forum, and was hosted by the Egyptian United Procurement Authority in the capital, Cairo.
If completed, this project will bring the first ever digitised, end-to-end mRNA production platform focused on mRNA vaccine production to the country — which will serve both the human and animal health markets.
By utilising Quantoom's Ntensify mRNA synthesis and formulation technologies in combination with DNA Script's DNA synthesis technologies, EVA Pharma can integrate this into its current vaccine development and manufacturing capabilities to create around 100 million doses of RNA-based vaccines per year.
Establishing regional autonomy
During recent months, Quantoom Biosciences has been collaborating with many countries across the globe who may not currently have RNA vaccine development and manufacturing capabilities.
This follows the company's initiative to enhance the global supply chain stability of mRNA-based vaccines, ensuring that more people across the world have access to such treatments.
Together with EVA Pharma and DNA Script, Quantoom hopes to bolster the region's vaccine manufacturing autonomy, while also enhancing Egypt's presence in the biopharmaceutical market.
This collaboration will focus on developing a next generation, saRNA-based vaccines, targeting both human and animal health under the One Health approach to create a stronger defense against zoonotic diseases from the source.
This initiative will contribute to achieve Africa CDC’s target of 60% local vaccine production by 2040 and Egypt’s ambitious goal to manufacture 385 million vaccine doses annually by 2030.
CEO of EVA Pharma, Dr Riad Armanious, commented: “This moment will reshape African and global health security as we know it.”
“Our cross-continental collaboration will empower patients with next-generation, scalable, and versatile solutions that transform what once took years into a process achievable in weeks. This is not tomorrow’s promise, it is today’s reality: with an operational biologics manufacturing site producing 100 million vials and 1.5 billion doses of animal health vaccine already commercialized, we have the infrastructure to streamline vaccine production using groundbreaking mRNA technology and ensuring unparalleled safety.”
“By dramatically reducing the time needed to produce DNA templates, and by enabling the synthesis of longer and more complex DNA sequences, we're helping ensure that innovative vaccine technology can reach those at highest risk during emerging epidemics more rapidly than ever before,” noted Marc Montserrat, CEO of DNA Script.
José Castillo, CEO of Quantoom Biosciences, added: “This collaboration showcases the transformative power of combining complementary expertise across borders. Together, we are not only advancing RNA technologies but also addressing global health inequities by making life-
saving vaccines and therapeutics accessible to underserved populations.”